{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:03:32Z","timestamp":1775181812230,"version":"3.50.1"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>\n            Background\u2003Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy subjects and this action is further delayed in patients with acute myocardial infarction. Intravenous P2Y12 inhibition might lead to more timely and potent anti-platelet effect in the context of emergency primary angioplasty, improving myocardial recovery.<\/jats:p><jats:p>\n            Objectives\u2003This article compares the efficacy of intravenous cangrelor versus ticagrelor in a ST-elevation myocardial infarction (STEMI) population treated with primary percutaneous coronary intervention (PPCI).<\/jats:p><jats:p>\n            Materials and Methods\u2003In an open-label, prospective, randomized controlled trial, 100 subjects with STEMI were assigned 1:1 to intravenous cangrelor or oral ticagrelor. The co-primary endpoints were platelet P2Y12 inhibition at infarct vessel balloon inflation time, 4 and 24 hours. Secondary endpoints included indices of coronary microcirculatory function: index of microvascular resistance (IMR), initial infarct size (troponin at 24 hours) and final infarct size at 12 weeks (cardiac magnetic resonance). Secondary endpoints included indices of coronary microcirculatory function (index of microvascular resistance [IMR]), initial infarct size (troponin at 24 hours), final infarct size at 12 weeks (cardiac magnetic resonance), corrected thrombolysis in myocardial infarction (TIMI) frame count, TIMI flow grade, myocardial perfusion grade, and ST-segment resolution (ClinicalTrials.gov NCT02733341).<\/jats:p><jats:p>\n            Results\u2003P2Y12 inhibition at first balloon inflation time was significantly greater in cangrelor-treated patients (cangrelor P2Y12 reaction unit [PRU] 145.2\u2009\u00b1\u200950.6 vs. ticagrelor 248.3\u2009\u00b1\u200955.1). There was no difference in mean PRU at 4 and 24 to 36 hours post-dosing. IMR, final infarct size, angiographic and electrocardiographic measures of reperfusion were all similar between groups.<\/jats:p><jats:p>\n            Conclusion\u2003Cangrelor produces more potent P2Y12 inhibition at the time of first coronary balloon inflation time compared with ticagrelor. Despite this enhanced P2Y12 inhibition, coronary microvascular function and final infarct size did not differ between groups.<\/jats:p>","DOI":"10.1055\/s-0039-1688789","type":"journal-article","created":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T22:40:10Z","timestamp":1558910410000},"page":"1171-1181","source":"Crossref","is-referenced-by-count":41,"title":["Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial"],"prefix":"10.1055","volume":"119","author":[{"given":"Salahaddin","family":"Ubaid","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Ford","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital, Glasgow, United Kingdom"},{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital, Glasgow, United Kingdom"},{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Murray","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wrigley","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazish","family":"Khan","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel L.","family":"Armesilla","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wolverhampton, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon N.","family":"Townend","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saib S.","family":"Khogali","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Munir","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Martins","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep S.","family":"Hothi","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa J.","family":"McAlindon","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Cotton","sequence":"additional","affiliation":[{"name":"Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom"},{"name":"School of Pharmacy, University of Wolverhampton, Wolverhampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,5,26]]},"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0039-1688789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T01:59:23Z","timestamp":1561427963000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0039-1688789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,26]]},"references-count":0,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2019,6,24]]},"published-print":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0039-1688789","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,26]]}}}